Literature DB >> 16142313

Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas.

Noriaki Tokumoto1, Satoshi Ikeda, Yasuyo Ishizaki, Takeshi Kurihara, Shinji Ozaki, Masahiko Iseki, Yosuke Shimizu, Toshiyuki Itamoto, Koji Arihiro, Masazumi Okajima, Toshimasa Asahara.   

Abstract

The mechanisms of carcinogenesis in intrahepatic cholangiocarcinoma (ICC) are not well characterized although alterations in several oncogenes and onco-suppressor genes have been reported to occur in ICC. In the present study, we focused on alterations in the Wnt signaling components and target genes by analyzing 24 surgically resected samples of ICC. Immunohistochemical analysis of beta-catenin showed positive staining in cytoplasm and/or nucleus in 58.3% of the samples, indicating the presence of alterations in the Wnt signaling pathway in these samples. In sequencing analyses, mutations in the beta-catenin, adenomatous polyposis coli and Axin 1 genes were observed in 8.3, 12.5 and 41.7%, respectively, of the 24 ICC samples; however, the functional significance of these mutated genes is controversial. Furthermore, cyclin D1, c-myc and urinary-type plasminogen activator receptor, which are the downstream target genes in the Wnt signaling pathway, were overexpressed in 41.7, 41.7 and 58.3%, respectively, of the 24 ICC samples. The overexpression of cyclin D1 was statistically correlated with that of beta-catenin. Based on these results, we speculated that the Wnt signaling pathway plays an important role in carcinogenesis in ICC through overexpression of its target genes, particularly cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142313

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  31 in total

1.  Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases.

Authors:  William B Laskin; Jerzy P Lasota; John F Fetsch; Anna Felisiak-Golabek; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

2.  JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.

Authors:  Patrick L Garcia; Aubrey L Miller; Tracy L Gamblin; Leona N Council; John D Christein; J Pablo Arnoletti; Marty J Heslin; Sushanth Reddy; Joseph H Richardson; Xiangqin Cui; Robert C A M van Waardenburg; James E Bradner; Eddy S Yang; Karina J Yoon
Journal:  Mol Cancer Ther       Date:  2017-11-15       Impact factor: 6.261

Review 3.  Genetic profiling of intrahepatic cholangiocarcinoma.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

4.  BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.

Authors:  Qin Lu; Xiwei Ding; Tianlu Huang; Shu Zhang; Yang Li; Lei Xu; Gang Chen; Yuyao Ying; Yun Wang; Zhenqing Feng; Lei Wang; Xiaoping Zou
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 5.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

6.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

Review 7.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

8.  Gene expression profiling in mouse liver infected with Clonorchis sinensis metacercariae.

Authors:  Dong Min Kim; Byung-Sam Ko; Jung-Won Ju; Shin-Hyeong Cho; Suk-Jin Yang; Young Il Yeom; Tong-Soo Kim; Yonggwan Won; Il-Chul Kim
Journal:  Parasitol Res       Date:  2009-11-10       Impact factor: 2.289

Review 9.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters.

Authors:  Bo Zhai; He-Xin Yan; Shu-Qin Liu; Lei Chen; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.